Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy

Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved unprecedented tumor regression in some patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Poznanski, Sophie M, Ritchie, Tyrah M, Fan, Isabella Y, El-Sayes, Abdullah, Portillo, Ana L, Ben-Avi, Ronny, Rojas, Eduardo A, Chew, Marianne V, Shargall, Yaron, Ashkar, Ali A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825270/
https://ncbi.nlm.nih.gov/pubmed/33479024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001933
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados